Related Experiment Video
Updated: Jun 21, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.6K
Infant acute lymphoblastic leukaemia-Progress from worldwide clinical efforts
Neil Barrett1, Tanja A Gruber2, Takako Miyamura3
1Department of Haematology, Children's Health Ireland, Dublin, Ireland.
British Journal of Haematology
|October 1, 2025
Summary
Infant acute lymphoblastic leukaemia (ALL) with KMT2A rearrangement is aggressive. Novel immunotherapies and targeted treatments like blinatumomab offer new hope, though challenges remain.
Area of Science:
- Hematology
- Pediatric Oncology
- Cancer Biology
Background:
- Infant acute lymphoblastic leukaemia (ALL) with KMT2A rearrangement presents a significant clinical challenge.
- Outcomes for infant ALL, particularly with KMT2A rearrangements, have lagged behind advances seen in childhood ALL.
- Traditional chemotherapy regimens have shown limited efficacy in this aggressive subtype.
Purpose of the Study:
- To review the current understanding and treatment landscape of KMT2A-rearranged infant ALL.
- To highlight recent advancements in therapeutic strategies, including immunotherapy and targeted agents.
- To discuss the challenges associated with novel treatment approaches.
Main Methods:
- Literature review focusing on KMT2A-rearranged infant ALL.
- Analysis of historical treatment outcomes.
- Evaluation of emerging immunotherapies and targeted therapies currently in clinical trials.
Main Results:
- Novel immunotherapies, such as blinatumomab, are being integrated into clinical trials for KMT2A-rearranged infant ALL.
- Targeted therapies, including venetoclax and menin inhibitors, show promise based on a deeper understanding of the disease biology.
- Despite progress, challenges in immunotherapy application require further investigation.
Conclusions:
- Significant progress has been made in understanding and treating KMT2A-rearranged infant ALL.
- Emerging therapies offer renewed optimism for improved patient outcomes.
- Addressing challenges in immunotherapy is crucial for future therapeutic success.
More Related Videos
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...